Juewan Kim1, Kyungwon Kang2, Christopher J Drogemuller2,3, Gordon G Wallace4, P Toby Coates5,6. 1. Department of Molecular & Cellular Biology, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia. 2. Discipline of Medicine, School of Medicine, The University of Adelaide, Adelaide, South Australia, 5000, Australia. 3. Central Northern Adelaide Renal and Transplantation Service (CNARTS), The Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia. 4. Intelligent Polymer Research Institute, ARC Centre of Excellence for Electromaterial Science, University of Wollongong, Wollongong, New South Wales, 2522, Australia. 5. Discipline of Medicine, School of Medicine, The University of Adelaide, Adelaide, South Australia, 5000, Australia. toby.coates@sa.gov.au. 6. Central Northern Adelaide Renal and Transplantation Service (CNARTS), The Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia. toby.coates@sa.gov.au.
Abstract
PURPOSE OF REVIEW: Pancreatic islet cell transplantation is currently the only curative cell therapy for type 1 diabetes mellitus. However, its potential to treat many more patients is limited by several challenges. The emergence of 3D bioprinting technology from recent advances in 3D printing, biomaterials, and cell biology has provided the means to overcome these challenges. RECENT FINDINGS: 3D bioprinting allows for the precise fabrication of complex 3D architectures containing spatially distributed cells, biomaterials (bioink), and bioactive factors. Different strategies to capitalize on this ability have been investigated for the 3D bioprinting of pancreatic islets. In particular, with co-axial bioprinting technology, the co-printability of islets with supporting cells such as endothelial progenitor cells and regulatory T cells, which have been shown to accelerate revascularization of islets and improve the outcome of various transplantations, respectively, has been achieved. 3D bioprinting of islets for generation of an artificial pancreas is a newly emerging field of study with a vast potential to improve islet transplantation.
PURPOSE OF REVIEW: Pancreatic islet cell transplantation is currently the only curative cell therapy for type 1 diabetes mellitus. However, its potential to treat many more patients is limited by several challenges. The emergence of 3D bioprinting technology from recent advances in 3D printing, biomaterials, and cell biology has provided the means to overcome these challenges. RECENT FINDINGS: 3D bioprinting allows for the precise fabrication of complex 3D architectures containing spatially distributed cells, biomaterials (bioink), and bioactive factors. Different strategies to capitalize on this ability have been investigated for the 3D bioprinting of pancreatic islets. In particular, with co-axial bioprinting technology, the co-printability of islets with supporting cells such as endothelial progenitor cells and regulatory T cells, which have been shown to accelerate revascularization of islets and improve the outcome of various transplantations, respectively, has been achieved. 3D bioprinting of islets for generation of an artificial pancreas is a newly emerging field of study with a vast potential to improve islet transplantation.
Entities:
Keywords:
3D bioprinting; Endothelial progenitor cell therapy; Pancreatic islet transplantation; Regulatory T cell therapy; Type 1 diabetes
Authors: A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: W Bennet; B Sundberg; C G Groth; M D Brendel; D Brandhorst; H Brandhorst; R G Bretzel; G Elgue; R Larsson; B Nilsson; O Korsgren Journal: Diabetes Date: 1999-10 Impact factor: 9.461
Authors: José Cornejo; Jorge A Cornejo-Aguilar; Mariela Vargas; Carlos G Helguero; Rafhael Milanezi de Andrade; Sebastian Torres-Montoya; Javier Asensio-Salazar; Alvaro Rivero Calle; Jaime Martínez Santos; Aaron Damon; Alfredo Quiñones-Hinojosa; Miguel D Quintero-Consuegra; Juan Pablo Umaña; Sebastian Gallo-Bernal; Manolo Briceño; Paolo Tripodi; Raul Sebastian; Paul Perales-Villarroel; Gabriel De la Cruz-Ku; Travis Mckenzie; Victor Sebastian Arruarana; Jiakai Ji; Laura Zuluaga; Daniela A Haehn; Albit Paoli; Jordan C Villa; Roxana Martinez; Cristians Gonzalez; Rafael J Grossmann; Gabriel Escalona; Ilaria Cinelli; Thais Russomano Journal: Biomed Res Int Date: 2022-03-24 Impact factor: 3.411